MARTI WILLEY: Open Payments
NPI 1144574062 · ENCINITAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,680 in 215 payments from 50 companies in 2025. Trend: 2023 $8,060 · 2024 $12,963 · 2025 $6,680
Food & beverage: $6,334Education: $337Long term medical supply or device loan: $83
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $768 |
| AstraZeneca Pharmaceuticals LP | 17 | $578 |
| ABBVIE INC. | 20 | $508 |
| Gilead Sciences, Inc. | 16 | $434 |
| PFIZER INC. | 15 | $413 |
| Eisai Inc. | 9 | $392 |
| Merck Sharp & Dohme LLC | 12 | $303 |
| GENZYME CORPORATION | 9 | $279 |
| Novartis Pharmaceuticals Corporation | 5 | $196 |
| Incyte Corporation | 5 | $195 |
Products named: RYBREVANT, EPKINLY, Lenvima, KEYTRUDA, SARCLISA, Trodelvy, TECVAYLI, ELREXFIO.
Industry payments across CA — which companies pay providers there.
